» Articles » PMID: 17991624

Rectum Dose Reduction and Individual Treatment Plan Optimization for High-dose-rate Prostate Brachytherapy

Overview
Journal Brachytherapy
Specialty Radiology
Date 2007 Nov 10
PMID 17991624
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Different doses and techniques used in high-dose-rate (HDR) prostate brachytherapy make it difficult to define universal quality parameters. The aim of this study was to develop individual, objective parameters for the evaluation of an HDR brachytherapy plan for prostate radiation.

Methods: Fifty-three patients who received an HDR brachytherapy boost after external radiation were analyzed in this study. Brachytherapy was performed with a (192)Ir source after ultrasound-guided, transperineal metal needle application followed by removal of the ultrasound probe to reduce organ dose levels at the anterior rectum wall. The rectum and prostate locations as well as the dose at the anterior rectum wall were estimated under the anatomical conditions of HDR prostate brachytherapy. The doses at the organs at risk (rectum and urethra) were analyzed for several parameters, which were compared to values of former patients before the start of treatment. In cases of major deviations, modifications of the treatment plan were performed before starting the treatment.

Results: Deflating of the water balloon led to an increase of the space between the anterior rectal wall and the dorsal margin of the prostate (mean, 6mm; 1-10mm). The dose of the introduced "virtual rectum," represented by the ventral surface of the ultrasound probe, in the treatment plan correlated to dose measurements in the rectum. Pretreatment evaluation and comparison of the established individual quality parameters led in two cases to a treatment plan modification.

Conclusions: This method allows a fast and objective individual brachytherapy treatment plan evaluation and improvement.

Citing Articles

Overview of treatment plan quality in a high dose rate prostate brachytherapy workflow.

Panetta J, Veltchev I, Horwitz E, Hallman M, Wong K, Price R Brachytherapy. 2024; 23(6):698-704.

PMID: 39343653 PMC: 11585429. DOI: 10.1016/j.brachy.2024.08.255.


An evaluation of the robustness of organ-at-risk recommendations made by GEC/ESTRO according to interobserver variability: a single-center experience.

Chicas-Sett R, Celada-Alvarez F, Roldan S, Torregrosa A, Betancourt J, Bautista-Ballesteros J J Contemp Brachytherapy. 2016; 8(4):349-55.

PMID: 27648090 PMC: 5018524. DOI: 10.5114/jcb.2016.61738.


Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.

Frohlich G, Agoston P, Lovey J, Somogyi A, Fodor J, Polgar C Strahlenther Onkol. 2010; 186(7):388-95.

PMID: 20582396 DOI: 10.1007/s00066-010-2081-x.